Sandra Fuentes
Overview
Explore the profile of Sandra Fuentes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leon-Justel A, Fernandez-Riejos P, Fuentes S, Martin S, Pareja-Mejia M, Martinez-Brocca M, et al.
Clin Lab
. 2025 Jan;
71(1.
PMID: 39808157
Background: Epidemics and pandemics have been shown to have widespread effects on health systems. Diabetes is a condition of particular risk during national emergencies such as the COVID-19 pandemic. The...
2.
Fuentes S, Arancibia D, Rojas M, Carmona F, Ortega A, Valenzuela J, et al.
ACS Omega
. 2024 Jul;
9(26):28061-28071.
PMID: 38973864
In this work, samarium-doped BaTiO (BT:Sm) nanoparticles (NPs) were prepared and coated with poly(ethylene glycol) (PEG) to investigate their optical characteristics and compatibility with biological systems. The structure, particle morphology,...
3.
Jimenez-Cortegana C, Salamanca E, Palazon-Carrion N, Sanchez-Jimenez F, Perez-Perez A, Vilarino-Garcia T, et al.
Front Immunol
. 2023 Nov;
14:1266659.
PMID: 38035104
SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences in the severity, complications and outcomes of the COVID-19 are intriguing and, patients...
4.
Jimenez-Cortegana C, Sanchez-Jimenez F, Perez-Perez A, Alvarez N, Sousa A, Canton-Bulnes L, et al.
Front Immunol
. 2022 Feb;
12:801410.
PMID: 35154077
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe...
5.
Navas D, Fuentes S, Castro-Alvarez A, Chavez-Angel E
Gels
. 2021 Dec;
7(4).
PMID: 34940335
Sol-Gel is a low cost, well-established and flexible synthetic route to produce a wide range of micro- and nanostructures. Small variations in pH, temperature, precursors, time, pressure, atmosphere, among others,...
6.
Martin S, Fuentes S, Sanchez C, Jimenez M, Navarro C, Perez H, et al.
Scand J Clin Lab Invest
. 2021 May;
81(4):282-289.
PMID: 33974458
Background: Early identification of patients with COVID-19 who may develop critical illness is of great importance. Methods: In this study a retrospective cohort of 264 COVID-19 cases admitted at Macarena...
7.
Fuentes S, Ravichandran S, Coyle E, Klenow L, Khurana S
iScience
. 2020 Mar;
23(3):100920.
PMID: 32145646
Limited knowledge exists on the quality of polyclonal antibody response generated following Ebola virus (EBOV) infection compared with vaccination. Polyclonal antibody repertoire in plasma following EBOV infection in survivors was...
8.
Fuentes S, Hahn M, Chilcote K, Chemaly R, Shah D, Ye X, et al.
J Infect Dis
. 2019 Nov;
221(4):636-646.
PMID: 31745552
Background: Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoietic cell transplant (HCT) recipients. However, antibody responses that correlate with recovery from RSV disease are not fully understood. Methods:...
9.
Fuentes S, Ravichandran S, Khurana S
J Infect Dis
. 2018 Jun;
218(suppl_5):S597-S602.
PMID: 29939294
Several Ebola vaccines and therapeutics are under clinical development. However, limited knowledge exists on the quality of antibody response generated by different Ebola vaccines. In this study, antibody repertoire induced...
10.
Fuentes S, Klenow L, Golding H, Khurana S
Sci Rep
. 2017 Feb;
7:42428.
PMID: 28186208
In current study, we evaluated the safety and protective efficacy of recombinant unglycosylated RSV G protein ectodomain produced in E. coli (in presence and absence of oil-in-water adjuvant) in a...